COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN

被引：0
|
作者：
Morimoto, K. [1 ]
Moriwaki, K. [2 ]
Shimozuma, K. [3 ]
Nakayama, T. [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
    Lam, Simon W.
    Wai, Maya
    Lau, Jessica E.
    McNamara, Michael
    Earl, Marc
    Udeh, Belinda
    PHARMACOTHERAPY, 2017, 37 (01): : 94 - 103
  • [22] Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer
    Hong-Dou Chen
    Jing Zhou
    Feng Wen
    Peng-Fei Zhang
    Ke-Xun Zhou
    Han-Rui Zheng
    Yu Yang
    Qiu Li
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 361 - 368
  • [23] Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer
    Chen, Hong-Dou
    Zhou, Jing
    Wen, Feng
    Zhang, Peng-Fei
    Zhou, Ke-Xun
    Zheng, Han-Rui
    Yang, Yu
    Li, Qiu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (02) : 361 - 368
  • [24] Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma
    Hindson J.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (8) : 523 - 523
  • [25] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [26] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB plus CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN JAPAN
    Akai, M.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S69 - S69
  • [27] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
    Hu, Huabin
    She, Longjiang
    Liao, Mengting
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Carbone, David P.
    Huang, Jin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [28] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [29] Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
    Huo, Gengwei
    Song, Ying
    Liu, Wei
    Guo, Hua
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] Cost-effectiveness of Paclitaxel plus Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan
    Saito, Shota
    Muneoka, Yusuke
    Ishikawa, Takashi
    Akazawa, Kouhei
    CLINICAL THERAPEUTICS, 2017, 39 (12) : 2380 - 2388
12345